Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oculus Issues Chinese Commercialization Plans For Microcyn Technology

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Oculus will formally begin commercializing its Microcyn technology-based Dermacyn products in China in cooperation with its Chinese partners China Bao Tai Investment and Sinopharm, the company announced May 5

You may also be interested in...



Pakistan Rolls Out The Carpet To Attract Global Clinical Trials

KARACHI - The Trade Development Authority of Pakistan will hold the country's first conference on clinical research April 26-27 in Karachi in an effort to better compete for global clinical trials with India and China, conference participants told PharmAsia News in a recent series of interviews

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

SC068473

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel